SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma

Published:2021-11-22 Issue:12 Volume:41 Page:
ISSN:0270-7306
Container-title:Molecular and Cellular Biology
language:en
Short-container-title:Mol Cell Biol

Author:

Rauth Sanchita¹,Karmakar Saswati¹,Shah Ashu¹,Seshacharyulu Parthasarathy¹,Nimmakayala Rama Krishna¹,Ganguly Koelina¹,Bhatia Rakesh¹,Muniyan Sakthivel¹,Kumar Sushil¹,Dutta Samikshan¹,Lin Chi²,Datta Kaustubh¹,Batra Surinder K.¹³,Ponnusamy Moorthy P.¹³^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA

2. Department of Radiation Oncology, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA

3. Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA

Abstract

RNA polymerase II-associated factor 1 (PAF1)/pancreatic differentiation 2 (PD2) is a core subunit of the human PAF1 complex (PAF1C) that regulates the RNA polymerase II function during transcriptional elongation. PAF1/PD2 has also been linked to the oncogenesis of pancreatic ductal adenocarcinoma (PDAC).

Funder

Foundation for the National Institutes of Health

Nebraska Department of Health and Human Services

Publisher

American Society for Microbiology

Subject

Cell Biology,Molecular Biology

Link

https://journals.asm.org/doi/pdf/10.1128/MCB.00135-21

Reference36 articles.

1. Cancer Statistics, 2021

2. Pancreatic cancer